<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYDROXYPROGESTERONE CAPROATE</span><br/>(hye-drox-ee-proe-jess'te-rone)<br/><span class="topboxtradename">Duralutin, </span><span class="topboxtradename">Gesterol L. A., </span><span class="topboxtradename">Hylutin, </span><span class="topboxtradename">Hyprogest 250, </span><span class="topboxtradename">Pro-Depo<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">progestin</span><br/><b>Prototype: </b>Progesterone<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>125 mg/mL; 250 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting synthetic progestational hormone. Has slower onset and longer action than progesterone. Has minimal estrogenic
         and androgenic activity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Induces and maintains endometrium, preventing uterine bleeding. Inhibits production of pituitary gonadotropin, preventing
         ovulation. Also produces thick cervical mucus resistant to passage of sperm.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Amenorrhea, abnormal uterine bleeding, advanced uterine cancer, and as "medical D &amp; C" (conversion of proliferative
         endometrium to secretory endometrium and desquamation). Also as a test for endogenous estrogen production.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe hepatic disease, carcinoma of breast or genital region; thromboembolic disorders, pregnancy (category X), lactation,
         missed abortion, abnormal vaginal bleeding.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Diabetes mellitus; asthma; epilepsy; migraine; cardiac or renal dysfunction; mental depression.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Amenorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 375 mg started anytime during cycle, after 4 d of desquamation or if no bleeding (21 d after injection, start cyclic therapy,
               repeat cyclic therapy q4wk and stop after 4 cycles)<br/><br/><span class="indicationtitle">Advanced Uterine Adenocarcinoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> <img src="../images/special/greaterorequal.gif"/>1 g at once, and repeat 1 or more times/wk, stop at time of relapse or if
               no desirable  results obtained after a total of 12 wk of therapy<br/><br/><span class="indicationtitle">Test for Endogenous Estrogen Production</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 250 mg at any time during cycle, repeat for confirmation 4 wk after first injection, stop after second injection<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Inject deep into a large muscle. Drug may cause local irritation at injection site.</li>
<li>Store preparation away from light at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Cerebral thrombosis or hemorrhage, migraine, depression. <span class="typehead"> CV:</span> Hypertension, thromboembolic disorders, e.g., <span class="speceff-life">pulmonary embolism</span>. <span class="typehead">GI:</span> Nausea, vomiting, cholestatic jaundice, abdominal cramps. <span class="typehead">Urogenital:</span> Breakthrough bleeding; changes in cervical erosion and secretions, changes in menstrual flow, dysmenorrhea; breast tenderness,
      enlargement, or secretion; vaginal candidiasis; female fetus masculinization. <span class="typehead">Respiratory:</span> Coughing, dyspnea, chest constriction. <span class="typehead">Skin:</span> Photosensitivity, acne, melasma, hirsutism, some loss of scalp hair, rash. <span class="typehead">Body as a Whole:</span> Edema, weight changes; allergy-like reactions (especially at high doses). <span class="typehead">Metabolic:</span> Decreased glucose tolerance. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Rifampin</b> may decrease pharmacologic effects of progestins. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 917 d. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Eliminated in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Record onset and duration of menstrual flow when drug is used to treat amenorrhea.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician immediately of suspected pregnancy, onset of vaginal bleeding, or thromboembolic implications (pain or numbness
            of legs, sudden onset of chest pain or shortness of breath, sudden severe headache or dizziness, visual problems).
         </li>
<li>Learn and perform breast self-examination.</li>
<li>Monitor blood glucose closely with diabetes.</li>
<li>Use sunscreen and protective clothing to reduce risk of photosensitivity.</li>
<li> 							Note: The onset of normal menstrual cycles may not occur for 2 or 3 mo after cessation of drug. 						</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>